Marker Change In Cash from 2010 to 2025

MRKR Stock  USD 1.28  0.03  2.40%   
Marker Therapeutics Change In Cash yearly trend continues to be relatively stable with very little volatility. Change In Cash is likely to grow to about 3.1 M this year. During the period from 2010 to 2025, Marker Therapeutics Change In Cash destribution of quarterly values had r-value of (0.06) from its regression line and median of  226,718. View All Fundamentals
 
Change In Cash  
First Reported
2000-03-31
Previous Quarter
-3.5 M
Current Value
1.2 M
Quarterly Volatility
M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Marker Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marker Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 M, Interest Expense of 12.9 K or Selling General Administrative of 5.6 M, as well as many indicators such as Price To Sales Ratio of 15.99, Dividend Yield of 0.0 or PTB Ratio of 3.26. Marker financial statements analysis is a perfect complement when working with Marker Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Marker Therapeutics Correlation against competitors.
To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.

Latest Marker Therapeutics' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Marker Therapeutics over the last few years. It is Marker Therapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Marker Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Very volatile
   Change In Cash   
       Timeline  

Marker Change In Cash Regression Statistics

Arithmetic Mean1,328,320
Coefficient Of Variation1,452
Mean Deviation10,837,363
Median226,718
Standard Deviation19,289,018
Sample Variance372.1T
Range88.3M
R-Value(0.06)
Mean Square Error397.4T
R-Squared0
Significance0.84
Slope(223,860)
Total Sum of Squares5581T

Marker Change In Cash History

20253.1 M
2024M
20233.3 M
2022-31.7 M
202122.1 M
2020-22.6 M
2019-17.8 M

About Marker Therapeutics Financial Statements

Marker Therapeutics shareholders use historical fundamental indicators, such as Change In Cash, to determine how well the company is positioned to perform in the future. Although Marker Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Marker Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Marker Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Change In CashM3.1 M

Additional Tools for Marker Stock Analysis

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.